Jeong, Lee, Kim, Chang, Han and Oh acquired 3.1% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for KRW 3.3 billion.
May 08, 2018
Share
Jeong, Lee, Kim, Chang, Han and Oh acquired 3.1% stake in SunBio,Inc. (XKON:A067370) from Kangpyung Telecom Co., Ltd. for KRW 3.3 billion on April 30, 2018. Under the terms of transaction, Jeong and others acquired 0.24 million shares at KRW 14000 each. Kangpyung Telecom will hold 0.074 million shares in SunBio,Inc after the deal from 0.31 million shares held earlier. Jeong acquired 0.07 million shares, Lee acquired 0.05 million shares, Kim acquired 0.03 million shares, Chang acquired 0.03 million shares, Han acquired 0.28 million shares and Oh acquired 0.28 million shares as part of the deal.
Jeong, Lee, Kim, Chang, Han and Oh completed the acquisition of 3.1% stake in SunBio,Inc. (XKON:A067370) from Kangpyung Telecom Co., Ltd. on April 30, 2018.
SunBio,Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. The Company operates its business through three segments. The Polyethylene Glycol (PEG) Derivative Product business segment is involved in the manufacturing and sale of PEG derivative products. The PEG derivatives are intermediate materials used in dermal filler, drug delivery systems, hydrogel, and nanotechnology. The Biosimilar Business segment is involved in the manufacturing and sale of royalty and technology transfer products. The main products are neutropenia treatment products, and hepatitis C treatment products. The New Drug Development Business segment is involved in the development of oxygen carriers, artificial blood, stroke aid agents, cartilage synovial fillers, dry mouth treatment drugs, and long-term preservatives.
SUNBIO,INC. 
